See more : Boosh Plant-Based Brands Inc. (VGGIF) Income Statement Analysis – Financial Results
Complete financial analysis of NanoViricides, Inc. (NNVC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NanoViricides, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- COSCO SHIPPING Development Co., Ltd. (CITAF) Income Statement Analysis – Financial Results
- Electriq Power Holdings, Inc. (ELIQ) Income Statement Analysis – Financial Results
- India Nippon Electricals Limited (INDNIPPON.NS) Income Statement Analysis – Financial Results
- Grande Asset Hotels and Property Public Company Limited (GRAND.BK) Income Statement Analysis – Financial Results
- Sydbank A/S (SYANY) Income Statement Analysis – Financial Results
NanoViricides, Inc. (NNVC)
About NanoViricides, Inc.
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 759.01K | 747.53K | 723.33K | 704.54K | 699.72K | 695.91K | 680.06K | 662.95K | 659.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -759.01K | -747.53K | -723.33K | -704.54K | -699.72K | -695.91K | -680.06K | -662.95K | -659.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.44M | 6.39M | 5.78M | 6.11M | 4.70M | 5.92M | 4.83M | 5.53M | 5.03M | 3.66M | 5.13M | 4.29M | 4.27M | 4.16M | 3.20M | 1.73M | 839.24K | 731.81K | 899.89K | 30.77K |
| General & Administrative | 3.08M | 2.55M | 2.33M | 2.63M | 3.30M | 2.74M | 4.50M | 4.07M | 3.83M | 3.40M | 3.54M | 2.30M | 1.82M | 2.27M | 1.74M | 1.09M | 1.95M | 2.35M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.08M | 2.55M | 2.33M | 2.63M | 3.30M | 2.74M | 4.50M | 4.07M | 3.83M | 3.40M | 3.54M | 2.30M | 1.82M | 2.27M | 1.74M | 1.09M | 1.95M | 2.35M | 1.70M | 35.23K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -142.67K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.52M | 8.94M | 8.11M | 8.74M | 8.00M | 8.66M | 9.33M | 9.60M | 8.86M | 7.06M | 8.67M | 6.59M | 6.08M | 6.43M | 4.94M | 2.82M | 2.79M | 3.08M | 2.60M | 66.01K |
| Cost & Expenses | 8.52M | 8.94M | 8.11M | 8.74M | 8.00M | 8.66M | 9.33M | 9.60M | 8.86M | 7.06M | 8.67M | 6.59M | 6.08M | 6.43M | 4.94M | 2.82M | 2.79M | 3.08M | 2.60M | 66.01K |
| Interest Income | 221.97K | 355.83K | 11.86K | 9.35K | 17.08K | 55.50K | 100.43K | 60.96K | 62.64K | 160.86K | 171.00K | 55.59K | 46.79K | 14.34K | 0.00 | 31.93K | 0.00 | 54.51K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 938.00 | 5.12K | 85.41K | 93.67K | 0.00 | 544.49K | 2.13M | 2.47M | 3.82M | 3.66M | 1.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 90.56K | 0.00 | 0.00 |
| Depreciation & Amortization | 759.01K | 747.53K | 723.33K | 704.54K | 699.72K | 695.91K | 680.06K | 662.95K | 659.55K | 302.74K | 212.01K | 219.65K | 219.65K | 527.74K | 90.29K | 12.29K | 13.47K | 36.30K | 44.56K | 0.00 |
| EBITDA | -7.76M | -7.84M | -7.38M | -8.03M | -7.30M | -7.96M | -8.59M | -8.94M | -8.20M | -6.76M | -8.46M | -7.56M | -5.99M | -5.95M | -4.65M | -2.83M | -2.73M | -3.03M | -2.55M | -66.01K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.52M | -8.94M | -8.11M | -8.74M | -8.00M | -8.66M | -9.33M | -9.60M | -8.86M | -7.06M | -8.67M | -6.59M | -6.08M | -6.43M | -4.94M | -2.82M | -2.79M | -3.08M | -2.60M | -66.01K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 221.97K | 354.90K | 6.74K | -78.08K | -5.45M | 235.24K | 761.71K | -703.77K | -1.87M | 4.86M | -4.93M | -2.29M | -125.46K | -47.71K | 358.27K | -26.20K | 53.70K | -36.05K | -688.58K | 0.00 |
| Income Before Tax | -8.29M | -8.59M | -8.11M | -8.82M | -13.45M | -8.42M | -8.56M | -10.30M | -10.72M | -2.20M | -14.11M | -8.88M | -6.21M | -6.48M | -4.74M | -2,787.80B | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 355.83K | -6.74K | 85.41K | -49.00K | -179.75K | 1.31M | 2.13M | 2.47M | 3.82M | 3.66M | 1.09M | 125.46K | 47.71K | -195.74K | 31.93B | -53.70K | 36.05K | 688.58K | 66.01K |
| Net Income | -8.29M | -8.59M | -8.10M | -8.91M | -13.40M | -8.24M | -8.56M | -10.30M | -10.72M | -2.20M | -14.11M | -8.88M | -6.21M | -6.48M | -4.74M | -2.79M | -2.74M | -3.12M | -3.28M | -66.01K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.70 | -0.74 | -0.70 | -0.82 | -2.39 | -2.30 | -2.64 | -3.43 | -3.72 | -0.78 | -5.51 | -3.87 | -2.90 | -3.26 | -2.54 | -1.63 | -1.64 | -1.94 | -2.22 | -0.05 |
| EPS Diluted | -0.70 | -0.74 | -0.70 | -0.82 | -2.39 | -2.30 | -2.64 | -3.43 | -3.72 | -0.74 | -5.51 | -3.73 | -2.90 | -3.26 | -2.54 | -1.63 | -1.64 | -1.94 | -2.22 | -0.05 |
| Weighted Avg Shares Out | 11.87M | 11.63M | 11.53M | 10.90M | 5.62M | 3.59M | 3.25M | 3.01M | 2.88M | 2.83M | 2.56M | 2.29M | 2.14M | 1.99M | 1.86M | 1.71M | 1.67M | 1.60M | 1.48M | 1.43M |
| Weighted Avg Shares Out (Dil) | 11.87M | 11.63M | 11.53M | 10.90M | 5.62M | 3.59M | 3.25M | 3.01M | 2.88M | 2.96M | 2.56M | 2.38M | 2.14M | 1.99M | 1.86M | 1.71M | 1.67M | 1.60M | 1.48M | 1.43M |
NanoViricides creating special purpose nanomaterials for antiviral therapy
As a war often accelerates technological innovation, the recent coronavirus pandemic in 2020 provided a big spur to advancements in biotechnology, with the rapid development of vaccines to contain the outbreak. One company that felt that boost is Connecticut-based firm,...
NanoViricides reveals promising efficacy of its antiviral drug candidate in combating RSV
NanoViricides Inc (NYSE-A:NNVC) has announced the promising efficacy of its antiviral drug candidate NV-387 in combating Respiratory Syncytial Virus (RSV) infection in an animal model. NV-387, the active ingredient of NV-CoV-2, the company's COVID treatment, has already entered Phase 1a/1b human...
Company's Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
SHELTON, CT / ACCESSWIRE / July 11, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today on the strong effectiveness of its broad-spectrum...
NanoViricides says clinical trial progressing satisfactorily for its broad-spectrum antiviral drug
NanoViricides Inc (NYSE-A:NNVC) has announced that the clinical trial of its broad-spectrum antiviral drug, NV-CoV-2, is progressing satisfactorily. The drug is being developed as a potential treatment for coronavirus infections, including COVID-19 and long COVID.
NanoViricides commences clinical trials for its broad-spectrum antiviral drug NV-CoV-2
NanoViricides Inc (NYSE-A:NNVC) has announced that clinical trials for its broad-spectrum antiviral drug NV-CoV-2 commenced on June 17, 2023. The trials will evaluate the safety and efficacy of two oral drug products: NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies.
The 7 Most Promising Penny Stocks to Buy in June
Some of the most promising penny stocks are up-and-coming and just just getting started. The world of penny stocks is all about speculating which young firms have the potential to become the next big companies.
NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET
SHELTON, CT / ACCESSWIRE / May 31, 2023 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at the BIO International Convention in Boston on June 5th,...
NanoViricides ends fiscal 3Q with strong cash runway to begin clinical trials of broad-spectrum COVID drug
NanoViricides (NYSE-A:NNVC) Inc has reported its financial results for the fiscal third quarter that revealed ample cash on hand, giving the company scope to kick off its clinical trials of its broad-spectrum antivirals, including lead COVID drug candidate NV-CoV-2. Investors...
NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City
SHELTON, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- (via IBN) -- NanoViricides, Inc. (NYSE American: NNVC ) (the “Company”), a clinical stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announces that...
NanoViricides, Inc. to Present at the Biotech Showcase(TM) 2023 Conference in San Fransisco on January 9th at 10:30am PT
SHELTON, CT / ACCESSWIRE / January 4, 2023 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at the Biotech Showcase™ 2023 Conference in San Fransisco on...
Source: https://incomestatements.info
Category: Stock Reports